文献速递神经核医学

帕金森综合征患者纹状体多巴胺转运体活性与18F-FP-CIT PET总生存期的关联

Association Between Dopamine Transporter Activity in the Striatum on 18 F-FP-CIT PET and Overall Survival of Patients With Parkinsonism.
PubMed 文献 · Clin Nucl Med · 2025-07-17

回顾性分析2021年3月至12月125例帕金森综合征患者的18F-FP-CIT PET,基于AI定量测量各纹状体亚区结合比。中位随访37个月,26例(20.8%)死亡;低尾状核结合比(≤1.63)组总生存期较差(HR 5.48,95%CI 1.27-23.59,P<0.001),多因素分析中低尾状核结合比(HR 5.360,95%CI 2.310-12.438,P<0.001)与高龄(HR 3.136,95%CI 1.356-7.251,P=0.008)均与更高死亡率显著相关。结论认为尾状核而非壳核的结合比可作为总生存期的显著预后指标。

要点

  • 低尾状核结合比(≤1.63)组总生存期较高结合比(>1.63)组差,HR 5.48(95%CI 1.27-23.59,P<0.001)。
  • 多因素分析中低尾状核结合比(HR 5.360,95%CI 2.310-12.438,P<0.001)与高龄(HR 3.136,95%CI 1.356-7.251,P=0.008)与更高死亡率显著相关。
  • 结论认为尾状核结合比而非壳核结合比可作为帕金森综合征患者总生存期的显著预后指标。

核心结论

  • 在帕金森综合征患者的FP-CIT PET中,尾状核而非壳核的结合比可作为总生存期的显著预后指标。
  • 作者认为无论定量数据还是视觉分析,尾状核的多巴胺转运体活性都应从预后角度获得更多关注。

研究设计与样本

  • 回顾性研究,回顾2021年3月至2021年12月帕金森综合征患者的18F-FP-CIT PET图像。
  • 最终队列125例,平均年龄73.1±9.4岁,中位随访37个月(范围31-41个月)。
  • 各纹状体区域多巴胺转运体活性以结合比(BR)表示,使用基于AI的定量软件(BTXBrain,v1.1.1)从PET DICOM文件自动测量。
  • 死亡数据来自韩国国民健康保险系统。
  • 采用独立t检验比较非存活者与存活者各区域BR,采用Kaplan-Meier曲线和log-rank检验比较各脑区低BR组与高BR组的总生存期,并采用单因素和多因素Cox回归计算风险比(HR)。

主要发现

  • 随访期间26例(20.8%)患者死亡。
  • 非存活者背侧纹状体(P=0.03)、尾状核(P≤0.001)、前腹侧壳核(P=0.029)、前苍白球(P=0.030)、腹侧纹状体(P=0.002)和丘脑底核(P=0.032)的BR显著低于存活者。
  • 低尾状核BR(≤1.63)组总生存期较高尾状核BR(>1.63)组差(HR 5.48,95%CI 1.27-23.59,P<0.001)。
  • 多因素分析中,高龄(HR 3.136,95%CI 1.356-7.251,P=0.008)和低尾状核BR(HR 5.360,95%CI 2.310-12.438,P<0.001)与更高死亡率显著相关。

关键数值与推荐

  • 尾状核BR阈值:低BR为≤1.63,高BR为>1.63。
  • 低尾状核BR(≤1.63)组较高尾状核BR(>1.63)组总生存期差,HR 5.48(95%CI 1.27-23.59,P<0.001)。
  • 多因素分析中低尾状核BR(≤1.63)与更高死亡率相关,HR 5.360(95%CI 2.310-12.438,P<0.001)。

临床怎么用

  • 作者认为,在帕金森综合征患者的FP-CIT PET中,尾状核而非壳核的结合比可作为总生存期的显著预后指标;无论定量数据还是视觉分析,尾状核的多巴胺转运体活性都应从预后角度获得更多关注。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether the overall survival (OS) of patients with parkinsonism is associated with dopamine transporter activity in the striatum measured by 18 F-N-(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane positron emission tomography ( 18 F-FP-CIT PET). METHODS: From March 2021 to December 2021, 18 F-FP-CIT PET images from patients with Parkinsonism were retrospectively reviewed. Dopamine transporter activity in each striatal region was automatically measured as striatal binding ratio (BR) from PET DICOM files using AI-based quantification (BTXBrain, v1.1.1). Mortality data were obtained from the National Health Insurance system in South Korea. Independent t test was performed to compare regional BRs between nonsurvivor and survivor groups. OS was then compared between low BR and high BR groups for each brain region using Kaplan-Meier curves and the log-rank test. Both univariate and multivariate Cox regression analyses were conducted to calculate hazard ratios (HRs). RESULTS: The final cohort comprised 125 patients (mean age: 73.1 ± 9.4 y) with a median follow-up period of 37 months (range: 31-41 mo). Twenty-six (20.8%) patients died during the follow-up period. Nonsurvivors showed significantly lower BRs in the dorsal striatum ( p =0.03), caudates ( p ≤ 0.001), ventroanterior putamen ( p =0.029), anterior pallidum ( p =0.030), ventral striatum ( p =0.002), and subthalamic nucleus ( p =0.032). Patients with low caudate BR (≤1.63) demonstrated poorer OS than those with high caudate BR (>1.63) (HR: 5.48, 95% CI: 1.27-23.59, p <0.001). In multivariate analysis, old age (HR: 3.136; 95% CI: 1.356-7.251; p =0.008) and low caudate BR (HR: 5.360; 95% CI: 2.310-12.438; p <0.001) were significantly associated with higher mortality. CONCLUSIONS: In FP-CIT PET of patients with parkinsonism, the binding ratio of the caudate nucleus rather than that of the putamen can serve as a significant prognostic indicator for overall survival. Dopamine transporter activity of the caudate should receive more attention from a prognostic perspective, both in quantified data and visual analysis.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lee Y, Lee TK, Oh YS, et al. Association Between Dopamine Transporter Activity in the Striatum on 18 F-FP-CIT PET and Overall Survival of Patients With Parkinsonism. Clin Nucl Med. 2025. PMID: 40674642. doi:10.1097/RLU.0000000000006033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。